Acta Scientific Microbiology (ISSN: 2581-3226)

Review Article Volume 5 Issue 10

Review - Schizophrenia: Current Research and Observations

Sanobar Pathan* and Meonis Pithawala

C.G Bhakta Institute of Biotechnology, India

*Corresponding Author: Sanobar Pathan, C.G Bhakta Institute of Biotechnology, India.

Received: August 22, 2022; Published: September 29, 2022

Abstract

Schizophrenia is significant mental illness that impairs person's ability to think, feel, and act. Schizophrenia patients may appear to be out of touch with reality. They may hear voices that others do not. Positive, Negative, and Cognitive symptoms are three types of schizophrenia symptoms. Schizophrenia can be caused by variety of factors, including genes, environment, or changes in brain structure. Schizophrenia affects less than 1% of general population, but 10% of those who have first-degree relatives with condition, such as parents, brothers, or sisters, are affected. Majority of people suffering with schizophrenia are not that aggressive; nonetheless, when schizophrenia is left untreated, risk of violence also increases. Neurodevelopment Hypothesis, Dopamine Hypothesis, and Glutamate Hypothesis are three possible biological theories for Schizophrenia. It's critical to assist someone with schizophrenia symptoms in receiving treatment as soon as feasible. Here Antipsychotic medicines and psychosocial therapy are two types of therapy that can help with symptoms. Family and friends may assist their loved ones with schizophrenia by assisting them in obtaining treatment and encouraging them to adhere to it.

Keywords: Schizophrenia; Current Research; Hallucination; Glutamate Hypothesis

References

  1. Lavretsky H. “History of Schizophrenia as Psychiatric Disorder”. In: Mueser KT, Jeste DV. Clinical Handbook of Schizophrenia. New York, New York: Guilford Press (2008): 3-12.
  2. Crismon L., et al. “Schizophrenia”. In: DiPiro JT, Talbert RL, Yee GC, et al, eds. Pharmacotherapy: Pathophysiologic Approach. 9th New York, New York: McGraw-Hill (2014): 1019-1046.
  3. Beck AT., et al. “Biological Contributions”. In: Schizophrenia: Cognitive Theory, Research, and Therapy. New York, New York: Guilford Press (2009): 30-61.
  4. Schwartz JH and Javitch JA. “Neurotransmitters”. In: Kandel ER, Schwartz JH, Jessell TM, et al, eds. Principles of Neural Science. 5th New York, New York: McGraw-Hill; (2013): 289-305.
  5. Stahl SM. “Psychosis and Schizophrenia”. In: Stahl SM, ed. Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 2nd Cambridge, United Kingdom: Cambridge University Press; (2000): 365-399.
  6. Spears NM., et al. “Clozapine treatment in polydipsia and intermittent hyponatremia”. Journal of Clinical Psychiatry 3 (1996): 123-128.
  7. Lieberman JA., et al. “Effectiveness of antipsychotic drugs in patients with chronic schizophrenia”. The New England Journal of Medicine12 (2005): 1209-1223.
  8. Kapur S and Mamo D. “Half century of antipsychotics and still central role for dopamine D2 receptors”. Progress in Neuro-Psychopharmacology and Biological Psychiatry7 (2003): 1081-1090.
  9. Meltzer L., et al. “Serotonin receptors: their key role in drugs to treat schizophrenia”. Progress in Neuro-Psychopharmacology and Biological Psychiatry7 (2003): 1159-1172.
  10. Nyberg S., et al. “Suggested minimal effective dose of risperidone based on PET measured D2 and 5-HT2A receptor occupancy in schizophrenic patients”. American Journal of Psychiatry6 (1999): 869-875.
  11. Haddad PM and Dursun SM. “Neurological complications of psychiatric drugs: clinical features and management”. Human Psychopharmacology 23 (2008): 15-26.
  12. Pierre JM. “Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management”. Drug Safety3 (2005): 191-208.
  13. DeLeon A., et al. “Aripiprazole: comprehensive review of its pharmacology, clinical efficacy, and tolerability”. Clinical Therapy5 (2004): 649-666.
  14. Harrison PJ. “Neuropathological effects of antipsychotic drugs”. Schizophrenia Research2 (1999): 87-99.
  15. Kane JM and Malhotra A. “Future of pharmacotherapy for schizophrenia”. World Psychiatry2 (2003): 81-86.
  16. Patel KR., et al. “Schizophrenia: Overview and Treatment Options”. T. 39.9 (2014): 638-645.
  17. “Schizophrenia”. The New England Journal of Medicine12 (2005): 1286-1288.
  18. Davis JM. “The Choice of Drugs for Schizophrenia”. The New England Journal of Medicine5 (2006): 518-520.

Citation

Citation: Sanobar Pathan and Meonis Pithawala. “Review - Schizophrenia: Current Research and Observations".Acta Scientific Microbiology 5.10 (2022): 47-53.

Copyright

Copyright: © 2022 Sanobar Pathan and Meonis Pithawala. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days

Indexed In






News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is November 30, 2022.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US